会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • THERAPEUTIC AGENT COMPRISING LIPOCALIN 2 AGAINST CANCER METASTASIS, AND METHODS OF EARLY DIAGNOSIS AND INHIBITION OF CANCER METASTASIS USING LIPOCALIN 2
    • 包含LOCOCALIN 2抗癌剂的治疗药物,以及早期诊断方法和使用LIPOCALIN 2抑制癌症METASTASIS
    • US20100256073A1
    • 2010-10-07
    • US12779911
    • 2010-05-13
    • Eun-kyoung LeeHo-jeong LeeKong-ju LeeJang-seong KimDoo-hong ParkYeup YoonHyun-jun KimIn-hwan Lim
    • Eun-kyoung LeeHo-jeong LeeKong-ju LeeJang-seong KimDoo-hong ParkYeup YoonHyun-jun KimIn-hwan Lim
    • A61K38/16A61P35/00A61P35/04
    • A61K38/1709A61K48/00C12N15/86C12N2740/15043
    • The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically. And, the diagnostic kit and the method for the selection of a metastasis risk group using the kit enable the selection of a metastasis risk group by measuring the level of lipocalin 2 in tumor tissues or in body fluid. Therefore, the kit and the method can contribute to the effective clinical control of a cancer patient. Further, the composition of the invention can be effectively used for the treatment of liver cancer owing to its liver cancer growth inhibitory effect.
    • 本发明涉及用于抑制癌症转移的药物组合物,更准确地说,涉及一种抗癌转移的新型药物组合物,其包含脂质运载蛋白2蛋白,编码该蛋白质的基因,含有表达载体转染的基因或表达载体的表达载体 有效成分,使用该组合物抑制癌症转移的方法,用于预测癌症转移的诊断试剂盒,使用试剂盒选择转移风险组的方法,用于抑制癌症生长的新型药物组合物 以及使用其抑制癌症生长的方法。 本发明的药物组合物特异性地抑制癌症转移,从而可以显着地改善癌症治疗的效果。 并且,使用该试剂盒的诊断试剂盒和选择转移风险组的方法能够通过测量肿瘤组织或体液中脂笼蛋白2的水平来选择转移风险组。 因此,试剂盒和方法可以有助于癌症患者的有效临床控制。 此外,本发明的组合物由于其肝癌生长抑制作用,可以有效地用于治疗肝癌。
    • 4. 发明申请
    • LINEAR DOUBLE-STRANDED RNA MOLECULE INTERFERING WITH DIFFERENT TARGET GENES
    • 线性双链RNA分子与不同目标基因的干扰
    • US20110008885A1
    • 2011-01-13
    • US12667738
    • 2008-07-07
    • Meehyein KimDuckhyang ShinHyeon LeeSoo In KimYeup Yoon
    • Meehyein KimDuckhyang ShinHyeon LeeSoo In KimYeup Yoon
    • C12N5/071C07H21/02C12N15/63
    • C12N15/111C12N2310/111C12N2310/14C12N2310/51
    • A linear double-stranded RNA molecule, which comprises two or more consecutively or convergently linked short interfering RNAs (siRNAs) each reducing the expression of one of different target genes, and a recombinant expression vector comprising double-stranded DNA sequence expressing the linear double-stranded RNA molecule are provided. The linear double-stranded RNA molecule or the recombinant expression vector is useful for a method of reducing expression of target genes in a cell, the method comprising introducing the linear double-stranded RNA molecule or the recombinant expression vector into the cell, whereby the encoded siRNAs target different genes and reduce expression of the target genes. It was also proved that effective gene silencing activity can be induced when each siRNA unit within the linear double-stranded RNA molecule has 18 to 24 nucleotides and, additionally, the gene silencing activity is not affected by inverted orientation of an siRNA.
    • 线性双链RNA分子,其包含两个或更多个连续或趋向连接的短干扰RNA(siRNA),每个短干扰RNA减少一个不同靶基因的表达;以及重组表达载体,其包含表达线性双链RNA的双链DNA序列, 提供了双链RNA分子。 线性双链RNA分子或重组表达载体可用于减少细胞中靶基因表达的方法,该方法包括将线性双链RNA分子或重组表达载体引入细胞,由此编码 siRNA靶向不同的基因并减少靶基因的表达。 还证明当线性双链RNA分子内的每个siRNA单元具有18至24个核苷酸时,可以诱导有效的基因沉默活性,此外,基因沉默活性不受siRNA反向取向的影响。